Back to Authors

Miller, Bruce L.

https://orcid.org/0000-0002-2152-4220

Mayo Clinic

University of California, San Francisco

Citations 127

An algorithm for genetic testing of frontotemporal lobar degeneration
Goldman, Jill , Rademakers, Rosa , Huey, Edward D. , Boxer, Adam L. , Mayeux, Richard , Miller, Bruce L. , Boeve, Bradley F. , Goldman, Jill S

Neurology | January 31, 2011 | Volume: 76 | Issue: 5 | Pages: 475-483

10.1212/wnl.0b013e31820a0d13 Get It

Off-Label Medication Use in Frontotemporal Dementia
Hu, Bei , Ross, Leslie , Kramer, Joel H. , Caselli, Richard J. , Graff‐Radford, Neill R. , Mendez, Mario F. , Boxer, Adam L. , Neuhaus, John M , Knopman, David S. , Boeve, Bradley F. , Miller, Bruce L. , Hu, Bei

American Journal of Alzheimer's Disease & Other Dementias® | February 1, 2010 | Volume: 25 | Issue: 2 | Pages: 128-133

10.1177/1533317509356692 Get It

Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimer’s Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer’s disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
Kramer, Joel H. , Caselli, Richard J., Graff‐Radford, Neill R. , Mendez, Mario F. , Mercaldo, Nathaniel D. , Knopman, David S. , Jack, Clifford R. , Boeve, Bradley F. , Miller, Bruce L. , Mercaldo, Nathaniel D

Neurology | May 26, 2009 | Volume: 72 | Issue: 21 | Pages: 1843-1849

10.1212/wnl.0b013e3181a71236 Get It

New Genes, New Dilemmas: FTLD Genetics and Its Implications for Families
Adamson, Jennifer, Karydas, Anna, Hutton, Mike, Goldman, Jill , Miller, Bruce L.

American Journal of Alzheimer's Disease & Other Dementias® | December 31, 2007 | Volume: 22 | Issue: 6 | Pages: 507-515

10.1177/1533317507306662 Get It

After Alzheimer's disease, frontotemporal lobar degeneration (FTLD) is the second leading cause of dementia in persons less than 65 years of age. Up to 40% of FTLD cases have a positive family history. Research on these families has led to the discovery of four disease-causing genes: microtubule-associated protein tau ( MAPT), progranulin ( PGRN), valosin-containing protein ( VCP), and charged multivesicular body protein 2B ( CHMP2B). MAPT and PGRN are responsible for the largest number of familial cases. Each of these genes differs by disease mechanism. Moreover mutations in both genes are associated with significant interfamilial and intrafamilial phenotypic variation. Genetic counseling needs to address the differences between the PGRN and MAPT mutations as well as the variation in clinical symptoms. The aims of this article are to describe the genetics of the FTLD spectrum and aid in the genetic counseling of individuals who may carry genetic mutations.
A 34-year-old man with progressive behavioral and language disturbance
Josephs, Keith A. , Parisi, Joseph E., Miller, Bruce L. , Keegan, B. Mark

Neurology | January 3, 2007 | Volume: 68 | Issue: 1 | Pages: 68-74

10.1212/01.wnl.0000251313.89403.b3 Get It